Screened 2026-07-19 · the tape above runs as of 22:40 UTC · 24 Jul · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Molina Healthcare, Inc. holds its Markdown at $225.37. Consolidating, no directional conviction, held for 24 days.
As held on the ledger · 2026-07-19
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 24 days
Price at the screen
$225.37
Valuation
60.26 trailing · 24.25 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.74
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-07-19 screen. The gold marker is the market price at the same screen. The price runs 8.3% above the base estimate.
Third-party analyst targets: 17 covering, consensus Hold. The average target sits −7% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-07-19 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Safety-net health plans priced above value
Molina runs the managed care plans that deliver Medicaid and Medicare coverage to low-income families across the United States. Picture the quiet contractor that actually processes the claims and keeps the state programmes running day to day.
The numbers give no reason to step in. Revenue is falling 4 percent, profit margins sit at zero and return on equity is just 4 percent. At 24 times forward earnings the shares trade 8 percent above our fair value with none of the growth or returns that would normally justify the premium.
Policy shifts on reimbursement rates and enrolment can swing results quickly in this regulated corner of healthcare. Thin margins leave little buffer if costs rise or rates are cut. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MOH trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-07-18Markdown$200.28+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 33%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (16 analysts) rates it hold, with a mean price target of $187.
2026-07-03Markdown$200.28+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markdown$200.28Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.